U.S. FDA panel recommends approval of Novo Nordisk diabetes drug
May 24 (Reuters) - A U.S. advisory panel on Tuesday recommended approval of a new diabetes drug made by Novo Nordisk A/S that combines two of its existing treatments in a fixed-dose combination designed to be both effective and convenient.
The panel voted 16-0 that the Food and Drug Administration should approve the drug, iDegLira, for patients with type 2 diabetes. The FDA is not obliged to follow the advice of its advisory panels but typically does so.
(Reporting by Toni Clarke in Washington; Editing by Chris Reese)
